Following almost of year of highly charged negotiations, the UK-EU trade and cooperation agreement will come into force on 1 January 2021, after it was signed by the presidents of the European Council and the European Commission on 30 December, one day before the expiry of the Brexit transition period.
EU-UK Trade Deal Allows For Mutual Recognition Of GMP Inspections
But No MRA For Batch Testing And Release
The trade deal agreed by the EU and the UK may have brought some relief to the life sciences sector in that it averts the chaos that would have followed failure to reach a deal, but it contains little that will have a direct impact on the regulation of medicines.
More from Europe
• By
Proposals to reform Spain’s reference pricing system are out of whack with the national pharmaceutical strategy published in December, six industry associations have warned.
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.
• By
The chair of a European Medicines Agency working group on reducing animal testing said that companies can provide “thoughts and suggestions” in relation to a review of its scientific guidelines on regulatory testing requirements and new approach methodologies.
• By
The European Medicines Agency’s latest move towards a more streamlined process for biosimilar registration in Europe was the hottest topic at last week’s annual biosimilars conference held by Medicines for Europe in Amsterdam.